background
investig
characterist
clinic
outcom
respiratori
syncyti
viru
rsv
relat
pediatr
intens
care
unit
picu
hospit
assess
palivizumab
pz
prophylaxi
elig
accord
differ
guidelin
korea
eu
usa
method
multicent
studi
children
year
age
hospit
six
picu
differ
hospit
due
sever
rsv
infect
septemb
march
includ
retrospect
chart
review
perform
result
total
patient
identifi
median
length
picu
stay
day
rang
day
median
picu
care
cost
rang
patient
year
old
begin
rsv
season
highrisk
patient
sever
rsv
infect
hemodynam
signific
congenit
heart
diseas
common
risk
factor
follow
chronic
lung
diseas
neuromuscular
diseas
congenit
abnorm
airway
nmdcaa
prematur
percentag
patient
elig
pz
prophylaxi
rang
base
guidelin
two
receiv
pz
day
prior
picu
admiss
median
durat
mechan
ventil
longer
children
ndmcaa
without
risk
factor
day
rang
day
vs
day
rang
day
p
rsvattribut
mortal
conclus
children
year
old
alreadi
wellknown
high
risk
repres
signific
proport
rsvrelat
picu
admiss
increas
complianc
pz
prophylaxi
practic
among
physician
need
studi
need
investig
burden
rsv
infect
patient
hospit
picu
includ
children
nmdcaa
key
word
elig
guidelin
neuromuscular
disord
congenit
abnorm
airway
pediatr
intens
care
unit
respiratori
syncyti
viru
respiratori
syncyti
viru
rsv
lead
caus
lower
respiratori
tract
infect
lrti
infant
young
children
caus
signific
socioeconom
burden
prematur
chronic
lung
diseas
cld
hemodynam
signific
congenit
heart
diseas
hschd
wellknown
highrisk
factor
sever
rsv
infect
highrisk
children
compris
approxim
rsvrelat
hospit
pediatr
intens
care
unit
picu
admiss
palivizumab
pz
human
monoclon
antibodi
rsv
f
protein
licens
prevent
rsvrelat
hospit
andor
picu
admiss
highrisk
children
admiss
picu
expens
term
medic
resourc
personnel
treatment
yet
need
updat
inform
patient
risk
factor
pz
usag
picu
hospit
despit
effect
pz
prophylaxi
elig
pz
vari
wide
countri
guidelin
updat
base
new
evid
also
base
chang
healthcar
polici
econom
statu
countri
american
academi
pediatr
aap
guidelin
one
new
risk
factor
pz
prophylaxi
sinc
neuromuscular
disord
andor
congenit
abnorm
airway
nmdcaa
includ
south
korean
eu
guidelin
addit
elig
pz
prophylaxi
prematur
infant
also
differ
countri
differ
age
restrict
use
defin
prematur
gestat
age
birth
chronolog
age
begin
rsv
season
studi
investig
characterist
children
admit
picu
due
rsv
infect
analyz
clinic
outcom
medic
cost
picu
care
elig
pz
prophylaxi
accord
differ
guidelin
children
age
year
hospit
six
picu
rsv
infect
septemb
march
includ
picu
tertiari
care
hospit
south
korea
samsung
medic
center
smc
seoul
asan
medic
center
seoul
korea
univers
ansan
hospit
ansan
gachon
univers
gill
hospit
incheon
pusan
nation
univers
children
hospit
yangsan
ewha
woman
univers
seoul
diagnosi
rsv
infect
confin
rsv
detect
h
picu
admiss
rapid
rsv
antigen
test
multiplex
respiratori
viru
realtim
polymeras
chain
reaction
pcr
andor
viral
cultur
respiratori
specimen
nasopharyng
endotrach
aspir
patient
underli
hematologyoncolog
diseas
rsv
infect
detect
h
picu
admiss
exclud
studi
approv
institut
review
board
samsung
medic
center
irb
particip
hospit
requir
inform
consent
assent
waiv
patientidentifi
data
delet
modifi
prior
analysi
retrospect
review
medic
record
includ
age
gender
underli
diseas
rsv
subtyp
method
rsv
detect
presenc
coinfect
sever
rsv
infect
lrti
defin
clinic
tachypnea
hypoxia
spo
requir
oxygen
supplement
chest
radiolog
confirm
pneumon
infiltr
hyperinfl
upper
respiratori
tract
infect
urti
defin
respiratori
symptom
without
hypoxia
normal
chest
radiolog
analyz
clinic
outcom
rsvrelat
picu
hospit
accord
risk
factor
clinic
outcom
paramet
length
picu
stay
preval
durat
mechan
ventil
support
rate
tracheostomi
day
mortal
patient
receiv
tracheostomi
assum
date
discontinu
ventil
support
date
transfer
gener
ward
high
risk
sever
rsv
infect
defin
base
previou
studi
guidelin
presenc
one
follow
risk
factor
prematur
gestat
age
week
cld
hschd
caa
nmd
syndrom
profound
immunocompromis
also
analyz
medic
cost
picu
hospit
smc
south
korea
rsv
season
span
autumn
earli
spring
xxxx
monitor
korea
influenza
respiratori
surveil
system
kinress
center
diseas
control
prevent
south
korea
typic
pz
prophylaxi
could
initi
septemb
given
monthli
march
limit
maximum
number
five
dose
pz
introduc
first
cover
nation
healthcar
insur
servic
south
korea
knhi
infant
young
children
cld
sinc
januari
infant
hschd
sinc
infant
born
prematur
gestat
age
week
sinc
infant
born
gestat
age
week
addit
circumst
children
age
month
hschd
cover
sinc
septemb
indic
includ
studi
compar
elig
pz
prophylaxi
patient
year
age
guidelin
three
differ
countriesregion
south
korea
knhi
coverag
indic
palivizumab
guidelin
updat
decemb
european
medicin
agenc
ema
guidelin
synagi
european
public
assess
reportproduct
inform
updat
decemb
us
aap
guidelin
modifi
recommend
use
palivizumab
prevent
rsv
infect
detail
pz
prophylaxi
elig
criteria
list
tabl
depend
purpos
analysi
patient
classifi
accord
differ
age
criteria
use
age
rsv
infect
analysi
clinic
outcom
addit
age
begin
rsv
season
year
use
analysi
pz
prophylaxi
continu
variabl
categor
variabl
summar
median
rang
frequenc
percentag
respect
clinic
outcom
accord
risk
factor
compar
use
mannwhitney
test
kruskalw
test
continu
variabl
fisher
exact
test
chisquar
test
univari
analysi
multipl
linear
regress
analysi
multipl
logist
regress
analysi
perform
adjust
age
diagnosi
gender
rsv
infect
clinic
diseas
statu
multivari
analysi
nonnorm
continu
outcom
logtransform
dunnett
test
appli
multipl
comparison
risk
group
nonrisk
group
multipl
linear
regress
p
consid
statist
signific
statist
analysi
carri
use
sa
version
sa
institut
cari
nc
usa
graphpad
prism
version
graphpad
softwar
la
jolla
ca
usa
total
pediatr
patient
admit
septemb
march
six
picu
rsv
detect
h
admiss
admiss
identifi
rsvrelat
picu
admiss
six
exclud
reason
fig
six
picu
admiss
due
rsv
infect
due
sever
progress
statu
underli
diseas
two
patient
enceph
admit
picu
decreas
mental
statu
respiratori
tract
infect
three
patient
congenit
heart
diseas
admit
picu
plan
open
heart
surgeri
rsv
infect
found
routin
activ
surveil
evalu
median
age
picu
admiss
month
rang
month
iqr
month
tabl
sixtynin
patient
year
age
time
rsv
infect
almost
half
month
age
fiftyf
patient
male
underli
diseas
six
patient
receiv
pz
prior
rsv
infect
two
receiv
pz
day
prior
picu
admiss
eightytwo
patient
present
lrti
present
urti
median
length
picu
stay
day
rang
day
iqr
day
half
patient
requir
mechan
ventil
median
durat
mechan
ventil
day
rang
day
iqr
day
three
patient
requir
tracheostomi
overal
day
mortal
n
five
case
ni
children
risk
factor
may
consid
prophylaxi
aap
american
academi
pediatr
caa
congenit
abnorm
airway
cld
chronic
lung
diseas
ema
european
medicin
agenc
ga
gestat
age
hschd
hemodynam
signific
congenit
heart
diseas
knhi
nation
healthcar
insur
servic
south
korea
ni
indic
nmd
neuromuscular
diseas
pz
palivizumab
fig
flow
case
select
two
exclud
case
enceph
one
listeria
meningoenceph
unknown
origin
boy
latter
case
patient
respiratori
symptom
except
fever
followup
test
neg
picu
pediatr
intens
care
unit
rsv
respiratori
syncyti
viru
death
relat
sever
rsv
infect
tabl
five
patient
die
high
risk
sever
rsv
infect
two
hschd
two
cld
one
prematur
infant
gestat
age
week
monthli
distribut
rsvrelat
picu
admiss
follow
season
pattern
rsv
circul
south
korea
increas
septemb
peak
octob
decemb
end
april
fig
rsv
season
septemb
march
rsvrelat
picu
hospit
occur
patient
year
age
time
rsv
infect
year
age
begin
overal
day
mortal
rsvattribut
day
mortal
prematur
n
chronic
lung
diseas
includ
bronchopulmonari
dysplasia
interstiti
lung
diseas
chronic
aspir
n
congenit
heart
diseas
n
neuromuscular
disord
due
mitochondri
diseas
spinal
muscular
atrophi
type
n
airway
malform
includ
tracheoesophag
fistula
lung
sequestr
tracheomalacia
tracheal
stenosi
n
chromosom
anomali
includ
syndrom
n
primari
immunodefici
n
acut
kidney
injuri
n
asthma
n
arterioven
malform
n
unknown
sever
development
delay
n
mediastin
lymphangiomatosi
n
nephrot
syndrom
n
renal
tubular
acidosi
type
n
megacyst
microcolon
syndrom
n
rsv
season
fig
fortynin
patient
least
one
risk
factor
sever
rsv
infect
regardless
age
fig
highrisk
children
picu
clinic
outcom
accord
risk
factor
rsvrelat
picu
admiss
children
year
age
begin
rsv
season
hschd
common
risk
factor
follow
cld
caa
prematur
nmd
six
patient
underli
diseas
increas
risk
sever
rsv
infect
patient
underli
diseas
rsvrelat
picu
admiss
children
year
age
time
rsv
infect
preval
mechan
ventil
significantli
higher
highrisk
group
norisk
group
multivari
analysi
vs
p
signific
differ
howev
outcom
paramet
length
picu
stay
durat
mechan
ventil
requir
tracheostomi
rsvrelat
day
mortal
nmdcaa
group
longer
median
durat
mechan
ventil
compar
norisk
group
day
rang
day
vs
day
rang
day
p
fig
tabl
estim
elig
pz
prophylaxi
accord
three
differ
guidelin
twentyfour
highrisk
children
elig
pz
prophylaxi
base
knhi
guidelin
base
ema
guidelin
base
aap
guidelin
tabl
knhi
guidelin
appear
restrict
aap
guidelin
regard
pz
elig
differ
signific
vs
p
fig
medic
cost
analyz
patient
hospit
smc
children
year
old
time
rsv
infect
median
cost
health
care
highrisk
group
appear
higher
norisk
group
although
differ
signific
rang
vs
rang
p
regard
patient
receiv
ventil
support
although
patient
risk
appear
higher
median
medic
cost
patient
risk
statist
signific
rang
vs
rang
p
tabl
studi
show
highrisk
children
account
high
proport
rsvrelat
picu
admiss
clinic
outcom
analysi
nmdcaa
associ
prolong
durat
mechan
ventil
elig
pz
prophylaxi
vari
accord
guidelin
differ
countri
proport
highrisk
patient
picu
higher
studi
berger
et
al
report
rsvrelat
intermedi
care
unit
imu
icu
admiss
children
year
age
switzerland
high
risk
least
one
risk
factor
prematur
gestat
age
week
cld
hschd
retrospect
studi
children
admit
picu
rsv
infect
canada
butt
et
al
found
underli
diseas
studi
howev
includ
nmdcaa
underli
diseas
nmdcaa
present
present
rsv
picu
case
preval
hschd
nmacaa
high
present
studi
compar
previou
studi
prematur
gestat
age
week
cld
rel
low
observ
might
due
differ
pz
prophylaxi
accord
risk
factor
differ
countri
retrospect
studi
rsvrelat
readmiss
preterm
infant
gestat
age
week
south
korea
lee
et
al
report
preterm
infant
receiv
pz
prophylaxi
includ
cld
high
pz
prophylaxi
rate
cld
prematur
infant
might
reduc
rsvrelat
picu
admiss
group
present
studi
infant
nmdcaa
elig
pz
prophylaxi
south
korea
studi
report
pz
prophylaxi
rate
children
hschd
recent
studi
infant
hschd
south
korea
report
receiv
pz
prophylaxi
time
addit
present
studi
period
includ
rsv
season
hschd
patient
elig
pz
prophylaxi
result
pz
prophylaxi
mani
children
hschd
might
delay
furthermor
shown
present
studi
even
accord
restrict
knhi
guidelin
patient
alreadi
elig
pz
prophylaxi
receiv
six
patient
howev
receiv
pz
least
picu
admiss
due
rsv
infect
therefor
also
import
promot
adher
pz
prophylaxi
highrisk
children
among
physician
daili
clinic
practic
current
pz
prophylaxi
guidelin
vari
greatli
countri
elig
pz
prophylaxi
present
patient
rang
base
guidelin
south
korea
eu
usa
main
differ
inclus
exclus
children
nmdcaa
differ
age
restrict
use
defin
prematur
hschd
age
restrict
use
identifi
highrisk
children
base
mani
studi
prophylact
effect
costbenefit
analys
contrast
children
nmdcaa
profound
immunocompromis
might
includ
current
guidelin
due
insuffici
data
effect
pz
prophylaxi
therefor
largescal
investig
prove
effect
pz
prophylaxi
highrisk
group
need
addit
although
doubt
syndrom
risk
factor
sever
rsv
infect
remain
controversi
whether
pz
prophylaxi
efficaci
includ
costbenefit
aspect
therefor
studi
need
notabl
although
number
patient
small
n
median
durat
mechan
ventil
significantli
longer
children
nmdcaa
n
risk
day
rang
day
vs
day
rang
day
p
tabl
children
nmd
caa
also
like
receiv
tracheostomi
children
norisk
group
borderlin
signific
vs
p
defect
respiratori
defens
mechan
impair
abil
clear
secret
andor
insuffici
cough
due
weak
respiratori
muscl
barrier
wean
children
mechan
ventil
although
insuffici
patient
nmd
caa
show
cost
differ
prolong
ventil
support
mean
longer
picu
care
requir
addit
medic
resourc
therebi
gener
larger
socioeconom
burden
tabl
given
retrospect
studi
focus
tertiarycar
hospit
like
children
sever
rsv
infect
sever
underli
diseas
includ
studi
includ
intermediatecar
hospit
addit
despit
multicent
studi
design
number
case
insuffici
subgroup
analysi
due
rariti
diseas
nevertheless
studi
provid
need
data
proport
highrisk
children
sever
rsv
infect
picu
pz
era
want
express
clinic
outcom
picu
admiss
due
sever
rsv
infect
includ
high
mortal
rate
well
econom
burden
picu
admiss
due
rsv
also
assess
elig
pz
prophylaxi
base
differ
guidelin
final
observ
children
nmdcaa
repres
signific
portion
picu
admiss
south
korea
children
elig
pz
prophylaxi
moreov
children
nmd
caa
appear
requir
prolong
durat
mechan
ventil
risk
therefor
worth
note
children
nmdcaa
might
compris
larger
portion
rsvrelat
picu
admiss
pz
prophylaxi
appropri
given
children
alreadi
wellknown
high
risk
accord
knhi
guidelin
conclus
south
korea
highrisk
children
repres
higher
proport
rsvrelat
picu
admiss
disclosur
yjk
receiv
grant
medimmun
rsv
research
receiv
grant
celltrion
research
rsvspecif
monoclon
antibodi
yjk
contract
janssen
rsv
research
author
declar
conflict
interest
